$0.5373
0.0974[22.14%]
At close: Apr 25
$0.5373
0[0.00%]
After Hours: 7:59PM EDT
TransCode Therapeutics
(NASDAQ:RNAZ)TransCode Therapeutics Stock (NASDAQ:RNAZ), Analyst Ratings, Price Targets, Predictions
TransCode Therapeutics Inc has a consensus price target of $3, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 16, 2024, April 3, 2024, and October 24, 2023. With an average price target of $3 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 458.35% upside for TransCode Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for TransCode Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | RNAZ | Buy Now | TransCode Therapeutics | $0.54 | 458.35% | HC Wainwright & Co. | Emily Bodnar | → $3 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | RNAZ | Buy Now | TransCode Therapeutics | $0.54 | 458.35% | HC Wainwright & Co. | Emily Bodnar | → $3 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | RNAZ | Buy Now | TransCode Therapeutics | $0.54 | 458.35% | HC Wainwright & Co. | Emily Bodnar | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | RNAZ | Buy Now | TransCode Therapeutics | $0.54 | 2133.39% | HC Wainwright & Co. | Emily Bodnar | → $480 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2022 | RNAZ | Buy Now | TransCode Therapeutics | $0.54 | 1016.69% | HC Wainwright & Co. | Emily Bodnar | $8000 → $4800 | Maintains | Buy | Get Alert |
| 06/07/2022 | RNAZ | Buy Now | TransCode Therapeutics | $0.54 | 1761.16% | HC Wainwright & Co. | Emily Bodnar | → $8000 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for TransCode Therapeutics (RNAZ)?
The latest price target for TransCode Therapeutics (NASDAQ: RNAZ) was reported by HC Wainwright & Co. on April 16, 2024. The analyst firm set a price target for $3.00 expecting RNAZ to rise to within 12 months (a possible 458.35% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TransCode Therapeutics (RNAZ)?
The latest analyst rating for TransCode Therapeutics (NASDAQ: RNAZ) was provided by HC Wainwright & Co., and TransCode Therapeutics reiterated their buy rating.
When was the last upgrade for TransCode Therapeutics (RNAZ)?
There is no last upgrade for TransCode Therapeutics.
When was the last downgrade for TransCode Therapeutics (RNAZ)?
There is no last downgrade for TransCode Therapeutics.
When is the next analyst rating going to be posted or updated for TransCode Therapeutics (RNAZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransCode Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransCode Therapeutics was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating TransCode Therapeutics (RNAZ) correct?
While ratings are subjective and will change, the latest TransCode Therapeutics (RNAZ) rating was a reiterated with a price target of $0.00 to $3.00. The current price TransCode Therapeutics (RNAZ) is trading at is $0.54, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.